AgomAb Therapeutics

Franklin Rooseveltlaan 348 126

9000 Gent

BE

AgomAb Therapeutics

Foundation date

13/04/2017

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

AgomAb is developing molecular therapies for the regeneration of damaged tissues. Our unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

Upcoming events

Latest news

  • Mithra appoints experienced life sciences executive Christian Homsy* as Chairman

    18 hours ago

  • Oxurion reaches enrollment target in KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema

    Friday May 26th 2023

  • How garbage disposal clogs in cells can lead to Alzheimer’s

    Friday May 26th 2023

Jobs by AgomAb Therapeutics